FDA Drug and Biologic Approvals for Neurology: 2017 Midyear Review

Seven new drugs were approved for treatment of neurological disorders, including Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis.

Related Videos
Related Content

Understanding the Risk of Multiple Sclerosis in Patients With HIV

March 28th 2023

Episode 84: Parkinson Disease Education for Community Providers

March 10th 2023

SYMBYX Neuro Light Therapy Wellness Helmet Positively Impacts Parkinson Disease Symptoms

March 25th 2023

Episode 83: The ARISE Study and Using DMTs in RIS

February 24th 2023

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

March 22nd 2023

This Week on NeurologyLive® — March 20, 2023

March 20th 2023

Understanding the Risk of Multiple Sclerosis in Patients With HIV

March 28th 2023

Episode 84: Parkinson Disease Education for Community Providers

March 10th 2023

SYMBYX Neuro Light Therapy Wellness Helmet Positively Impacts Parkinson Disease Symptoms

March 25th 2023

Episode 83: The ARISE Study and Using DMTs in RIS

February 24th 2023

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

March 22nd 2023

This Week on NeurologyLive® — March 20, 2023

March 20th 2023

Understanding the Risk of Multiple Sclerosis in Patients With HIV

March 28th 2023

Episode 84: Parkinson Disease Education for Community Providers

March 10th 2023

SYMBYX Neuro Light Therapy Wellness Helmet Positively Impacts Parkinson Disease Symptoms

March 25th 2023

Episode 83: The ARISE Study and Using DMTs in RIS

February 24th 2023

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

March 22nd 2023

This Week on NeurologyLive® — March 20, 2023

March 20th 2023
© 2023 MJH Life Sciences

All rights reserved.